

AMENDMENTS

The Claims:

1. (Previously presented) A combination product comprising at least one antisense oligonucleotide of the gene encoding MBD2 demethylase and at least one agent used in antitumor chemotherapy, for simultaneous or separate use for the treatment of proliferative and inflammatory diseases.
2. (Previously presented) The combination product of claim 1, wherein the antisense of the gene encoding MBD2 demethylase comprises at least:
 - a) 15 consecutive nucleotides of the sequence SEQ ID No. 1 or of the sequence complementary thereto, or
 - b) a sequence capable of hybridizing selectively with one of the sequences defined in a).
3. (Previously presented) The combination product of one of claim 1 or 2, wherein the agent used in antitumor chemotherapy is a compound belonging to the bleomycin family.

Claims 4-6. (Canceled).

7. (Previously presented) The combination product of claim 1, wherein the antisense oligonucleotide of the gene encoding MBD2 demethylase is in a vector comprising a promoter which allows its effective expression in a eukaryotic cell.
8. (Previously presented) The combination product of claim 7, which further comprises a poly A transcription termination sequence.

9. (Previously presented) The combination product of claim 7, wherein the vector is a plasmid.

10. (Previously presented) The combination product of claim 1, wherein the antisense oligonucleotide is a double-stranded DNA.

11. (Previously presented) The combination product of claim 10, which further comprises one or more elements which promote the transfer of the antisense oligonucleotide into the target cells.

12. (Previously presented) The combination product of claim 11, wherein the antisense oligonucleotide is suitable for administration in vivo by electrotransfer.

13. (Previously presented) The combination product of claim 12, further comprising one or more pharmaceutically acceptable vehicle(s).

14. (Previously presented) The combination product of claim 13, for simultaneous or separate use in the treatment of cancer.

15. (Previously presented) The combination product of claim 14, which is suitable for administration by intratumor injection.

16. (Previously presented) The combination product of claim 3, wherein said compound is bleomycin.

Claims 17-28. (Canceled).

29. (Previously presented) The combination product of claim 12, wherein the electro transfer is by weak electric fields of between 1 and 600 V/cm.

30. (Previously presented) A combination product comprising at least one MBD2 antisense oligonucleotide and bleomycin, wherein said bleomycin is formulated for injection into a subject and said oligonucleotide is formulated for administration via electronic transfer carrying 500 V/cm current, and for administration about 30 minutes after the injection of the bleomycin.